Pharmaceuticals (Jun 2020)

Bone-Seeking Matrix Metalloproteinase Inhibitors for the Treatment of Skeletal Malignancy

  • Antonio Laghezza,
  • Luca Piemontese,
  • Leonardo Brunetti,
  • Alessia Caradonna,
  • Mariangela Agamennone,
  • Antonella Di Pizio,
  • Giorgio Pochetti,
  • Roberta Montanari,
  • Davide Capelli,
  • Marilena Tauro,
  • Fulvio Loiodice,
  • Paolo Tortorella

DOI
https://doi.org/10.3390/ph13060113
Journal volume & issue
Vol. 13, no. 6
p. 113

Abstract

Read online

Matrix metalloproteinases (MMPs) are a family of enzymes involved at different stages of cancer progression and metastasis. We previously identified a novel class of bisphosphonic inhibitors, selective for MMPs crucial for bone remodeling, such as MMP-2. Due to the increasing relevance of specific MMPs at various stages of tumor malignancy, we focused on improving potency towards certain isoforms. Here, we tackled MMP-9 because of its confirmed role in tumor invasion, metastasis, angiogenesis, and immuno-response, making it an ideal target for cancer therapy. Using a computational analysis, we designed and characterized potent MMP-2/MMP-9 inhibitors. This is a promising approach to develop and clinically translate inhibitors that could be used in combination with standard care therapy for the treatment of skeletal malignancies.

Keywords